| SEC Form 4 |  |
|------------|--|
|------------|--|

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| ) | Check this box if no longer subject to<br>Section 16. Form 4 or Form 5<br>obligations may continue. See |
|---|---|
|   | Instruction 1(b).   |

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL |           |  |  |  |  |  |  |
|--------------|-----------|--|--|--|--|--|--|
| OMB Number:  | 3235-0287 |  |  |  |  |  |  |
|              |           |  |  |  |  |  |  |

| Estimated average burden | 0.5 |
|--------------------------|-----|
| hours per response:      | 0.5 |

| 1. Name and Address of Reporting Person <sup>*</sup><br>BOGER JOSHUA S |         |       | 2. Issuer Name and Ticker or Trading Symbol<br>VERTEX PHARMACEUTICALS INC /<br><u>MA</u> [ VRTX ] |                         | ionship of Reporting Person<br>all applicable)<br>Director<br>Officer (give title<br>below) | n(s) to Issuer<br>10% Owner<br>Other (specify<br>below) |  |
|--|---------|-------|---|-------------------------|---|---|--|
| (Last) (First) (Middle)<br>C/O VERTEX PHARMACEUTICALS<br>INCORPORATED  |         | ,     | 3. Date of Earliest Transaction (Month/Day/Year)<br>09/21/2011                                    |                         | Delow)  | Delow)  |  |
| 130 WAVERLY ST   |         |       | 4. If Amendment, Date of Original Filed (Month/Day/Year)  | 6. Indivi<br>Line)      | vidual or Joint/Group Filing (Check Applica   |   |  |
| (Street)   |         |       |   | X Form filed by One Rep |   |   |  |
| CAMBRIDGE  | MA      | 02139 |   |                         | Form filed by More than C<br>Person   | One Reporting   |  |
| (City)   | (State) | (Zip) |   |                         |   |   |  |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transa<br>Code (<br>8) |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |               |                                  | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |
|---------------------------------|--|---|------------------------------|---|--|---------------|----------------------------------|---|---|---|
|                                 |  |   | Code                         | v | Amount   | (A) or<br>(D) | Price                            | Reported<br>Transaction(s)<br>(Instr. 3 and 4)                |   | (Instr. 4)  |
| Common Stock                    | 09/21/2011                                 |   | М                            |   | 4,000  | A             | \$24.66                          | 731,395   | D   |   |
| Common Stock                    | 09/21/2011                                 |   | <b>S</b> <sup>(1)</sup>      |   | 2,300  | D             | <b>\$52.54</b> <sup>(2)(3)</sup> | 729,095   | D   |   |
| Common Stock                    | 09/21/2011                                 |   | <b>S</b> <sup>(1)</sup>      |   | 1,700  | D             | <b>\$53.55</b> <sup>(3)(4)</sup> | 727,395   | D   |   |
| Common Stock                    |  |   |                              |   |  |               |                                  | 13,286  | Ι   | 401(k)  |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| Derivative<br>Security<br>(Instr. 3) Conversion<br>or Exercise<br>Price of<br>Derivative Date<br>(Month/Day/Year) Execution Date,<br>if any<br>(Month/Day/Year) Transaction<br>Code (Instr.<br>8) of<br>Derivative<br>Securities<br>Acquired Expiration Date<br>(Month/Day/Year) Amount of<br>Securities<br>Underlying Derivative<br>Securities<br>Underlying Derivative<br>Security<br>(Instr. 5) Ownership<br>Securities Of Indi<br>Securities   Derivative<br>(Instr. 3) Date Execution Date,<br>(Month/Day/Year) Transaction<br>Securities Of<br>Securities Derivative<br>Securities Derivative<br>Securities Ownership<br>Securities |                                       |      |      |            |                        |                  |                                   |                     |                    |                 |  |                                       |  |                                      |  |                                  |                                       |
|---|---------------------------------------|------|------|------------|------------------------|------------------|-----------------------------------|---------------------|--------------------|-----------------|--|---------------------------------------|--|--------------------------------------|--|----------------------------------|---------------------------------------|
| Derivative<br>Security  | Conversion<br>or Exercise<br>Price of | Date | Date | Date       | Execution Date, if any | Transa<br>Code ( | Transaction<br>Code (Instr.<br>3) |                     | ivative<br>urities | Expiration Date |  | Amount of<br>Securities<br>Underlying |  | Derivative<br>Security<br>(Instr. 5) | e derivative<br>Securities<br>Beneficially | Ownership<br>Form:<br>Direct (D) | Beneficial<br>Ownership<br>(Instr. 4) |
|   |                                       |      |      | Code       | v                      | (A)              | (D)                               | Date<br>Exercisable | Expiration<br>Date | Title           | Amount<br>or<br>Number<br>of<br>Shares |                                       |  |                                      |  |                                  |                                       |
| Stock<br>Option   |                                       |      | (5)  | 12/10/2011 | Common<br>Stock        | 4,000            | \$0.00                            | 40,946              | D                  |                 |  |                                       |  |                                      |  |                                  |                                       |

Explanation of Responses:

1. Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

2. Open market sales reported on this line occurred at a weighted average price of \$52.54 (range \$52.00 to \$52.99).

3. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

4. Open market sales reported on this line occurred at a weighted average price of \$53.55 (range \$53.03 to \$54.04).

5. Fully vested.

Remarks:

#### Valerie L. Andrews, Attorney-

In-Fact

09/22/2011

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.